Enanta Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

Enanta Pharmaceuticals Inc share price today is $12.53, up -3.77%. The stock opened at $12.975 against the previous close of $13, with an intraday high of $12.975 and low of $12.49.

Enanta Pharmaceuticals Inc Share Price Chart

Enanta Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
us-stock

Enanta Pharmaceuticals Inc Share Price Performance

$12.53 -0.0377(-3.77%) ENTA at 23 Mar 2026 12:53 PM Biotechnology
Lowest Today 12.49
Highest Today 12.975
Today’s Open 12.975
Prev. Close 13
52 Week High 17.15
52 Week Low 4.09
Day’s Range: Low 12.49 High 12.975
52-Week Range: Low 4.09 High 17.15
1 day return -
1 Week return -2.48
1 month return -6.82
3 month return -22.62
6 month return +63.09
1 year return +102.25
3 year return -68.37
5 year return -76.31
10 year return -

Enanta Pharmaceuticals Inc Institutional Holdings

Farallon Capital Management, L.L.C. 9.55

Krensavage Asset Management, LLC 9.53

Vanguard Group Inc 7.93

HHG PLC 6.71

BlackRock Inc 6.32

Acadian Asset Management LLC 2.99

Vanguard Total Stock Mkt Idx Inv 2.94

Millennium Management LLC 2.31

iShares Russell 2000 ETF 2.30

Geode Capital Management, LLC 2.23

Renaissance Technologies Corp 2.21

BlackRock Health Sciences Opps Inv A 1.71

State Street Corp 1.63

Hillsdale Investment Management Inc. 1.46

Spruce Street Capital LP 1.34

Marshall Wace Asset Management Ltd 1.33

Hillsdale US Small Cap Eq Fund Srs A U$ 1.22

Vanguard Strategic Small-Cap Equity Inv 1.09

Point72 Asset Management, L.P. 1.03

Vanguard Institutional Extnd Mkt Idx Tr 0.98

Two Sigma Investments LLC 0.98

Morgan Stanley - Brokerage Accounts 0.97

Fidelity Small Cap Index 0.92

JPMorgan Chase & Co 0.85

iShares Russell 2000 Value ETF 0.83

AQR Capital Management LLC 0.81

Charles Schwab Investment Management Inc 0.75

Dimensional Fund Advisors, Inc. 0.73

iShares Biotechnology ETF 0.71

Vanguard Strategic Equity Inv 0.62

Vanguard VIF Small Co Gr 0.54

Fidelity Extended Market Index 0.47

State St Russell Sm/Mid Cp® Indx SL Cl I 0.45

Vanguard Russell 2000 ETF 0.45

Schwab US Small-Cap ETF™ 0.43

Vanguard Explorer Inv 0.41

BlackRock Advantage Small Cap Core Instl 0.35

Invesco Dorsey Wright SmallCap Momt ETF 0.31

State St Russell Sm Cap® Indx SL Cl I 0.29

iShares Micro-Cap ETF 0.25

Enanta Pharmaceuticals Inc Market Status

Strong Buy: 2

Buy: 1

Hold: 2

Sell: 1

Strong Sell: 0

Enanta Pharmaceuticals Inc Fundamentals

Market Cap 363.03 M

PB Ratio 2.9801

PE Ratio 0.0

Enterprise Value 248.47 M

Total Assets 280.73 M

Volume 199671

Enanta Pharmaceuticals Inc Company Financials

Annual Revenue FY25:65324000 65.3M, FY24:67635000 67.6M, FY23:79204000 79.2M, FY22:86160000 86.2M, FY21:97074000 97.1M

Annual Profit FY25:60738000 60.7M, FY24:67635000 67.6M, FY23:79204000 79.2M, FY22:86160000 86.2M, FY21:97074000 97.1M

Annual Net worth FY25:-81889000 -81.9M, FY24:-116045000 -116.0M, FY23:-133816000 -133.8M, FY22:-121755000 -121.8M, FY21:-78996000 -79.0M

Quarterly Revenue Q4/2025:18615000 18.6M, Q3/2025:15125000 15.1M, Q2/2025:18314000 18.3M, Q1/2025:14926000 14.9M, Q4/2024:16959000 17.0M

Quarterly Profit Q4/2025:18615000 18.6M, Q3/2025:15125000 15.1M, Q2/2025:18314000 18.3M, Q1/2025:14926000 14.9M, Q4/2024:16959000 17.0M

Quarterly Net worth Q4/2025:-11938000 -11.9M, Q3/2025:-18700000 -18.7M, Q2/2025:-18255000 -18.3M, Q1/2025:-22644000 -22.6M, Q4/2024:-22290000 -22.3M

About Enanta Pharmaceuticals Inc & investment objective

Company Information Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Organisation Biotechnology

Employees 120

Industry Biotechnology

CEO Dr. Jay R. Luly Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Enanta Pharmaceuticals Inc FAQs

What is the share price of Enanta Pharmaceuticals Inc today?

The current share price of Enanta Pharmaceuticals Inc is $12.53.

Can I buy Enanta Pharmaceuticals Inc shares in India?

Yes, Indian investors can buy Enanta Pharmaceuticals Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Enanta Pharmaceuticals Inc shares in India?

You can easily invest in Enanta Pharmaceuticals Inc shares from India by:

Can I buy fractional shares of Enanta Pharmaceuticals Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Enanta Pharmaceuticals Inc?

Enanta Pharmaceuticals Inc has a market cap of $363.03 M.

In which sector does Enanta Pharmaceuticals Inc belong?

Enanta Pharmaceuticals Inc operates in the Biotechnology sector.

What documents are required to invest in Enanta Pharmaceuticals Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Enanta Pharmaceuticals Inc?

The PE ratio of Enanta Pharmaceuticals Inc is N/A and the PB ratio is 2.98.